NUTRIBAND INC. DL -,001 Aktie

Nutriband released results for the quarter ended July 31, 2026, reporting a loss per share of $0.07. Revenue amounted to $0.4 million, 29.03% below the prior year’s $0.6 million. The figures were presented on September 4, 2026, at a financial conference. » More on finanzen.net

At the annual general meeting, shareholders elected seven directors for one year and confirmed Sadler, Gibb & Associates as auditors. The number of authorized preferred shares was increased from 10 million to 20 million; the advisory vote on executive compensation was approved to be held annually. The board also appointed Alessandro Puddu and Viorica Carlig, and the company announced the sale of 90% of subsidiary Pocono Pharmaceutical to EarthVision for $5 million as well as a letter of intent with the Qvanta Group to explore quantum-AI cooperation. Nutriband continues work on the Aversa fentanyl patch, while for 2026 a loss per share of -$0.61 is forecast despite an expected 28% increase in revenue. » More on de.investing.com

Nutriband has appointed Alessandro Puddu and Viorica Carlig to its board of directors and reports key milestones for the Aversa fentanyl patch, including an enhanced partnership with Kindeva, scaling of the commercial manufacturing process, and a Type-C meeting with the FDA. For 2026 the company plans a full patent filing (protection possibly through 2046), production of study material, an IND submission, and the start of clinical studies on abuse potential. Financial data show a market capitalization of around $55 million, more cash than liabilities, and analyst forecasts for 2026 with EPS of -0.61; the stock trades well below its 52-week high. Nutriband has also filed a complaint with FINRA alleging naked short selling and notes outstanding warrant expiration dates in October 2026. » More on de.investing.com